Kayothera

🚀 Exciting News from Kayothera! 🧬💊 We're excited to announce the expansion of our Scientific Advisory Board to advance our mission of developing groundbreaking therapies: Chaired by Yibin Kang, PhD, Warner-Lambert/Parke-Davis Professor of Molecular Biology at the Ludwig Institute of Princeton University, members include:  🧬Domenico Accili, MD, Professor of Medicine at Columbia University and the Director of the Columbia University Diabetes Research Center. Dr. Accili is the 2017 Banting Medal Recipient and is highly recognized for his pioneering work on beta cell failure in type 2 diabetes and the treatment of type 1 diabetes through enteroendocrine cell conversion; 🧬Shridar Ganesan, PhD/MD, a prominent physician-scientist and medical oncologist at the NYU Perlmutter Cancer Center, where he serves as the Director for the Center for Molecular Oncology and Professor of Medicine; 🧬Suzanne George, MD, a renowned clinical expert in sarcoma, serving as the clinical director of the Center for Sarcoma and Bone Oncology at Dana-Farber Cancer Institute and an associate professor of Medicine at Harvard Medical School; and 🧬Kendall Mohler, PhD, was previously co-founder and chief scientific officer at Trubion Pharmaceuticals, the founding CSO at Juno Therapeutics, and a senior leader at Immunex, where he played a key role in the development of Enbrel (etanercept). This SAB will provide crucial insights as we develop our first-in-class, oral, small-molecule retinoid nuclear receptor pathway inhibitors.

🚀 Exciting News from Kayothera! 🧬💊 We're excited to announce the expansion of our Scientific Advisory Board to advance our mission of developing groundbreaking therapies: Chaired by Yibin Kang, PhD, Warner-Lambert/Parke-Davis Professor of Molecular Biology at the Ludwig Institute of Princeton University, members include:  🧬Domenico Accili, MD, Professor of Medicine at Columbia University and the Director of the Columbia University Diabetes Research Center. Dr. Accili is the 2017 Banting Medal Recipient and is highly recognized for his pioneering work on beta cell failure in type 2 diabetes and the treatment of type 1 diabetes through enteroendocrine cell conversion; 🧬Shridar Ganesan, PhD/MD, a prominent physician-scientist and medical oncologist at the NYU Perlmutter Cancer Center, where he serves as the Director for the Center for Molecular Oncology and Professor of Medicine; 🧬Suzanne George, MD, a renowned clinical expert in sarcoma, serving as the clinical director of the Center for Sarcoma and Bone Oncology at Dana-Farber Cancer Institute and an associate professor of Medicine at Harvard Medical School; and 🧬Kendall Mohler, PhD, was previously co-founder and chief scientific officer at Trubion Pharmaceuticals, the founding CSO at Juno Therapeutics, Inc. Therapeutics, and a senior leader at Immunex, where he played a key role in the development of Enbrel (etanercept). This SAB will provide crucial insights as we develop our first-in-class, oral, small-molecule retinoid nuclear receptor pathway inhibitors. #ScientificAdvisoryBoard #BiotechLeaders #LifeSciences

🚀 Exciting News from Kayothera! 🧬💊 We're thrilled to announce the expansion of our Board of Directors to advance our mission in developing groundbreaking therapies. We’re pleased to welcome to our new Board members: * Bruce Carter, PhD, (Chairman) - Former CEO of ZymoGenetics, brings 40+ years of biotech expertise * Paul Sekhri - Current CEO of vTv Therapeutics, with 30+ years in life sciences Their combined experience in drug development and biotech leadership will be instrumental in guiding Kayothera's growth and innovation. Welcome Bruce and Paul. 🔗 Click https://lnkd.in/gv345PnG to read the full press release. #Biotech #DrugDiscovery #LeadershipAnnouncement #KayotheraNews

Excited to share the latest article in the Journal of Experimental Medicine on the intricate role of Vitamin A and retinoid signaling in human health! This publication highlights the crucial work we're doing at KayoThera in inhibiting this pathway. While Vitamin A is essential for our well-being, too much of it—or the use of synthetic retinoids—can lead to serious health issues, including hyperlipidemia, heart failure, hypothyroidism, and even a delayed cancer-promoting effect. This paper dives deep into how diseases like #diabetes, #obesity, and #cancer exploit this nuclear receptor pathway and explores new therapeutic strategies to combat these conditions. Many thanks to Mark Esposito, Ph.D, Yibin Kang, and John Amory for their vital contributions to this article. Your expertise and collaboration were instrumental in bringing this research to life! https://lnkd.in/gkd9VpUm

Excited for another insightful presentation by Mark Esposito, Ph.D🧬📊 Can't wait to hear his latest findings and contributions to the field. #Science #Research #Innovation #FASEB2024

We are thrilled to announce that Mark Esposito, Ph.D will be speaking at the International Retinoids Conference VII on Monday, July 8th, during Session 3. If you are attending the Federation of American Societies for Experimental Biology (FASEB) Science Research Conference in Saint Paul, be sure to join us for his talk on “ALDH1a Enzyme Expression Activates Retinoid Nuclear Receptor Signaling to Drive Disease Progression in Diabetes, Obesity, and Cancer.” #IRSRC #retinoid

At #BIO2024? Don't miss the opportunity to meet NIH funded companies at NIH SEED booth 825 from 1:00-2:30 on Monday, June 3rd. Discover the advancements in drug and biologics development through non-dilutive funding. Learn more about #SBIR and #STTR. AAVogen, Accuronix Therapeutics, Inc., DermaXon, Philippe Diaz, Fabio Tucci, Extend Biosciences, Inc., Tarik S., Hillhurst Biopharmaceuticals, Inc., Andrew Gomperts, Dean Petkanas, Kannalife Sciences, Inc., KayoThera, Merika Koday, PhD, Lynthera Corporation, Kat McCormick, PhD, Novoron Bioscience, Conor Cullinane, PhD, Pirouette Medical, Janak Padia, PRIMETIME LIFE SCIENCES, LLC, StemSynergy Therapeutics, Inc., David R. Craig, MBA, Sarcometrics, Karl Ruping, Tiba Biotech, TransCode Therapeutics, Inc., Zdravka Medarova, Tania Montgomery, David Mead, Terra Bioforge, Ventrix, Cuthbert Simpkins, Vivacelle Bio, Inc.

We are thrilled to announce that KayoThera, Inc. has been selected for the NIH Company Showcase at #BIO2024 in San Diego. This prestigious opportunity will allow us to share the latest updates on our pipeline on a global stage. We are profoundly honored and grateful for the support of the National Institutes of Health. Join Mark Esposito, Ph.D, Vice President of R&D and co-founder, on Wednesday, June 5 at 11:45 AM in Company Presentation Theater 4, located in Hall A of the Exhibition Hall. See you in sunny San Diego! #nih #bio2024

I'm excited to be attending #bio2024 in San Diego along with 45 cutting edge life science innovators, all of whom have built their products in part with non-dilutive funds given by one of the 24 Institutes of the #NIH. Of these, 30 will be with me at booth #825. These are all companies now looking for venture investment, #pharma partners, and/or strategic relationships -- and it's fair to say that having been selected for our Showcase program, they are all poised to improve the standard of care across their sectors. I'll share the names of these 30 below. If you'd like our team to put together introductions specific to your area of interest, please DM me. Regardless of what you may be looking for, there's a good chance one or more of these companies fits your checklist. AAVogen Accuronix Therapeutics, Inc. Biopico Systems INC Concerto Biosciences DermaXon Extend Biosciences, Inc. Lectenz Bio GSNO Therapeutics Hillhurst Biopharmaceuticals, Inc. Immuto Scientific Indee Labs Invivo Science International Inc Kannalife, Inc. KayoThera Lynthera Corporation Medosome Biotec Modality.AI Devine Biosystems Novoron Bioscience Pelagos Pharma Pirouette Medical Reveal Pharmaceuticals Sinopia Biosciences Sacromatrix Talus Bio Tiba Biotech TransCode Therapeutics, Inc. Ventrix Vivacelle Bio, Inc. Buel D. (a.k.a. Dan) Rodgers Bradley Keller John Collins Philippe Diaz Tarik S. Lori Yang Andrew Gomperts Faraz A. Choudhury, Ph.D. ryan P. Ayla Annac Dean Petkanas Merika Koday, PhD Jeff Yang David R. Craig, MBA Conor Cullinane, PhD